Publication:
Risk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC)

Simple item page
dc.conference.dateMAR 30-APR 02, 2022
dc.conference.titleEuropean Lung Cancer Congress (ELCC)
dc.contributor.authorTrigo, J.
dc.contributor.authorCho, B. C.
dc.contributor.authorPark, K.
dc.contributor.authorGirard, N.
dc.contributor.authorViteri, S.
dc.contributor.authorGarrido, P.
dc.contributor.authorKrebs, M. G.
dc.contributor.authorThayu, M.
dc.contributor.authorKnoblauch, R. E.
dc.contributor.authorXie, J.
dc.contributor.authorBauml, J. M.
dc.contributor.authorSchnepp, R. W.
dc.contributor.authorLondhe, A.
dc.contributor.authorMahadevia, P.
dc.contributor.authorLeighl, N.
dc.contributor.authoraffiliation[Trigo, J.] Hosp Univ Virgen Victoria & Reg, IBIMA, Malaga, Spain
dc.contributor.authoraffiliation[Cho, B. C.] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea
dc.contributor.authoraffiliation[Park, K.] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea
dc.contributor.authoraffiliation[Girard, N.] Inst Curie, Thorax Inst, Paris, France
dc.contributor.authoraffiliation[Viteri, S.] UOMI Canc Ctr, Clin Mi Tres Torres, Barcelona, Spain
dc.contributor.authoraffiliation[Garrido, P.] Hosp Univ Ramon & Cajal, IRYCIS, Madrid, Spain
dc.contributor.authoraffiliation[Krebs, M. G.] Univ Manchester, Fac Biol Med & Hlth, Div Canc Sci, Manchester, Lancs, England
dc.contributor.authoraffiliation[Krebs, M. G.] Christie NHS Fdn Trust, Manchester Acad, Hlth Sci Ctr, Manchester, Lancs, England
dc.contributor.authoraffiliation[Thayu, M.] Janssen R&D, Spring House, PA USA
dc.contributor.authoraffiliation[Knoblauch, R. E.] Janssen R&D, Spring House, PA USA
dc.contributor.authoraffiliation[Xie, J.] Janssen R&D, Spring House, PA USA
dc.contributor.authoraffiliation[Bauml, J. M.] Janssen R&D, Spring House, PA USA
dc.contributor.authoraffiliation[Schnepp, R. W.] Janssen R&D, Spring House, PA USA
dc.contributor.authoraffiliation[Londhe, A.] Janssen R&D, Spring House, PA USA
dc.contributor.authoraffiliation[Mahadevia, P.] Janssen R&D, Spring House, PA USA
dc.contributor.authoraffiliation[Leighl, N.] Princess Margaret Canc Ctr, Toronto, ON, Canada
dc.contributor.funderJanssen RD
dc.date.accessioned2023-05-03T14:39:04Z
dc.date.available2023-05-03T14:39:04Z
dc.date.issued2022-04-02
dc.identifier.doi10.1016/j.annonc.2022.02.029
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753422001454/pdf
dc.identifier.urihttp://hdl.handle.net/10668/21888
dc.identifier.wosID778453100021
dc.issue.number2
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationHospital Universitario Virgen de la Victoria
dc.organizationInstituto de Investigación Biomédica de Málaga-IBIMA
dc.page.numberS38-S39
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleRisk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC)
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number33
dc.wostypeMeeting Abstract
dspace.entity.typePublication

Files

Collections

SAS - Hospital Universitario Virgen de la Victoria
Instituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía